More recently, due to the ongoing obesity epidemic and the better outcomes of the newer AOMs (i.e., GLP-1 medications), some plan sponsors are either choosing to add anti-obesity coverage in their pharmacy benefit or are at least considering doing so
The Tirzepatide segment is expected to grow at a CAGR of 12.87% during the forecast period due to its dual GIP/GLP-1 receptor mechanism, superior weight-loss efficacy demonstrated in comparative clinical studies, and expanding regulatory approvals across metabolic disease indications
Neuronal lipid metabolism: multiple pathways driving functional outcomes in health and disease
Get immediate clinical help for frustrating numbness, tingling, or nerve-related "pins and needles" sensations caused by a systemic B12 deficiency
Free radicals can damage skin cells and contribute to aging, and glutathiones antioxidant properties may help counteract these effects